Phase I–II Targeted Treatments
Fig. 13.1 A pharmacologic audit trail for clinical trial design. Solid boxes contain the conceptualized trial framework; dashed boxes demonstrate the example of a new therapy targeting androgen receptor (AR)…
ONCOLOGY
Cytotoxic Chemotherapy (Taxanes and Taxane Combinations)
Fig. 8.1 Proposed model of taxane mechanism of action in prostate cancer. AR associates with microtubules and translocates to the nucleus via the motor protein dynein. Taxanes inhibit depolymerization of…
Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development
© Springer Science+Business Media New York 2014Fred Saad and Mario A. Eisenberger (eds.)Management of Castration Resistant Prostate CancerCurrent Clinical Urology10.1007/978-1-4939-1176-9_23 23. Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design…
Defining Clinical Endpoints in Castration-Resistant Prostate Cancer
© Springer Science+Business Media New York 2014Fred Saad and Mario A. Eisenberger (eds.)Management of Castration Resistant Prostate CancerCurrent Clinical Urology10.1007/978-1-4939-1176-9_14 14. Defining Clinical Endpoints in Castration-Resistant Prostate Cancer Jorge A. Garcia1, 2 and Robert Dreicer1, 2 (1) Department…
Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors)
Fig. 7.1 Schema showing mechanism of action of CYP 17 and CYP 17 Inhibitor abiraterone acetate (AA). Note that upon inhibition of CYP 17 the mineralocorticoid path can be activated,…
Introduction
Targeted treatment combined with docetaxel Phase I docetaxel combination trial in CRPC, N Any unexpected safety signals? Pharmacodynamic studies Phase II docetaxel-combination trial in CRPC design (N) Statistical plan Primary…
Angiogenesis Inhibition in Castration-Resistant Prostate Cancer
Fig. 15.1 TGF-β transforming growth factor-β; HGF hepatocyte growth factor; VEGF vascular endothelial growth factor; PLGF placental growth factor; Ang angiopoietin; PDGF platelet-derived growth factor; FGF fibroblast growth factor Although…
Targeting C-Met/VEGF in Castration Resistant Prostate Cancer
Fig. 19.1 Schematic examples of HGF/MET and/or VEGF/VEGFR inhibitors mechanism of action. VEGFR vascular endothelial growth factor receptor, PDGFR platelet-derived growth factor receptor, HGF hepatocyte growth factor, FLT3 FMS-like tyrosine…
Bone-Targeted Therapy: Rationale and Current Status
Fig. 10.1 The vicious cycle of bone metastases Transforming growth factor beta (TGFβ) is released from resorbed bone matrix and has been shown to augment signaling through parathyroid hormone-related protein…
Molecular Mechanisms of Prostate Cancer Progression After Castration
Phenotype Molecular basis Mechanism Consequence AR-addicted Adrenal or intra-tumoral androgen biosynthesis Androgens produced sufficient to activate AR Responds to androgen biosynthesis inhibitors and selected AR antagonists AR mutation Alters ligand…
